Primary source
OpenAI acquires Orchestra Bio OpenAI News
What we know
Confirmed by several sources
- OpenAI acquired Orchestra Bio. — TechCrunch, Techmeme, OpenAI News
Reported by one source
- OpenAI plans to add Orchestra Bio’s team and technology to Rosalind and Rosalind Workbench. — TechCrunch
- Orchestra Bio builds AI agents to help pharmaceutical companies manage drug development. — Techmeme
- Orchestra Bio’s technology is intended to support life sciences R&D and help biopharma teams advance drug development. — OpenAI News
Coverage 3 publishers
OpenAI NewsFirst reportPrimary source
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.
-
OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development, the ChatGPT maker shared exclusively with Axios.
-
OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.
Earliest report first. Articles stay on their publishers’ sites; each link opens the original.